Log in

Relevant bibliographies by topics / Sirolimus-eluting stent (SES) / Journal articles

To see the other types of publications on this topic, follow the link: Sirolimus-eluting stent (SES).

Journal articles on the topic 'Sirolimus-eluting stent (SES)'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Sirolimus-eluting stent (SES).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Hu, Patrick P., and Ehtisham Mahmud. "Sirolimus Eluting Stents." Clinical Medicine Insights: Therapeutics 2 (January 2010): CMT.S2094. http://dx.doi.org/10.4137/cmt.s2094.

Full text

Abstract:

The sirolimus-eluting stent (SES) Cypher was the first commercially available drug-eluting stent. The use of this stent has resulted in significantly lower rates of restenosis and lesion revascularization compared to bare metal stents and balloon angioplasty. In this review, angiographic and clinical outcomes in patients treated with SES are compared to those treated with bare metal stents and other drug-eluting stents. Furthermore, efficacy and safety outcomes of SES in complex lesions (left main stenosis, bifurcation lesions, chronic total occlusions, long lesions and small vessels) and high

APA, Harvard, Vancouver, ISO, and other styles

2

Adriano Dourado. "Comparative Clinical Performance of Two Types of Drug-Eluting Stents with Abluminal Biodegradable Polymer Coating: Five-Year Results of the DESTINY Randomized Trial." Revista Científica Hospital Santa Izabel 6, no. 3 (2022): 159–64. http://dx.doi.org/10.35753/rchsi.v6i3.332.

Full text

Abstract:

Introduction and Objectives: The Stents Coated with the Biodegradable Polymer on Their Abluminal Faces and Elution of Sirolimus versus Biolimus Elution for the Treatment of de Novo Coronary Lesions - DESTINY Trial is a non-inferiority randomized study that compared the InspironTM sirolimus-eluting stent (SES) with the control BiomatrixTM Flex biolimus-eluting stent (BES). Previous reports in the first year showed similar outcomes for both stents, in clinical, angiographic, optical coherence tomography, and intravascular ultrasound assessments. The present analysis aims to compare the clinical

APA, Harvard, Vancouver, ISO, and other styles

3

Almasood, Ali S., Xavier Freixa, Sohail Q. Khan, Peter H. Seidelin, and Vladimír Džavík. "Stent Fracture after Everolimus-Eluting Stent Implantation." Cardiology Research and Practice 2011 (2011): 1–5. http://dx.doi.org/10.4061/2011/320983.

Full text

Abstract:

Compared with bare-metal stents, drug-eluting stents (DES) have greatly reduced the risk of in-stent restenosis (ISR) by inhibiting neointimal growth. Nevertheless, DES are still prone to device failure, which may lead to cardiac events. Recently, stent fracture (SF) has emerged as a potential mechanism of DES failure that is associated with ISR. Stent fracture is strongly related to stent type, and prior reports suggest that deployment of sirolimus eluting stents (SES) may be associated with a higher risk of SF compared to other DES. Everolimus eluting stents (EESs) represent a new generation

APA, Harvard, Vancouver, ISO, and other styles

4

Leshkevich, Ch F., E. V. Kovsh, G. A. Sergeev, A. B. Maximchik, D. N. Boncevich, and I. E. Adzerikho. "ASSESSMENT OF INTERVENTION TREATMENT OF UNSTABLE ANGINA OF PATIENTS OF DIABETES MELLITUS TYPE 2." Health and Ecology Issues, no. 4 (December 28, 2008): 34–39. http://dx.doi.org/10.51523/2708-6011.2008-5-4-6.

Full text

Abstract:

The purpose of the study is a comparative assessment of the immediate and long-term results using Sirolimus - Eluting Stents (SES) and Bare-Metal Stent (BMS) in patients with unstable angina and diabetes mellitus type 2.

APA, Harvard, Vancouver, ISO, and other styles

5

Jimba, Takahiro, Takehiro Hashikata, Masashiro Matsushita, and Masao Yamasaki. "Repetitive restenosis in a biodegradable polymer sirolimus-eluting stent with hypersensitivity reaction: a case report." European Heart Journal - Case Reports 4, no. 1 (2020): 1–5. http://dx.doi.org/10.1093/ehjcr/ytaa001.

Full text

Abstract:

Abstract Background Hypersensitivity reaction is a classic cause of in-stent restenosis (ISR) in coronary stents, typically reported in bare-metal stents and first-generation drug-eluting stents. Biodegradable polymer sirolimus-eluting stent (BP-SES) was developed with the concept of biocompatibility, and there has been no report of ISR of BP-SES with hypersensitivity reaction. Case summary An 81-year-old woman presented with ST-elevation acute inferior myocardial infarction. Primary percutaneous coronary intervention was performed for the culprit lesion in the left circumflex artery with a pe

APA, Harvard, Vancouver, ISO, and other styles

6

Koppara, Tobias, Michael Joner, Gerd Bayer, Kristin Steigerwald, Tobias Diener, and Eric Wittchow. "Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation." Thrombosis and Haemostasis 107, no. 06 (2012): 1161–71. http://dx.doi.org/10.1160/th12-01-0043.

Full text

Abstract:

SummaryBiodegradable stent coatings were recently introduced as a potential solution to overcome sustained inflammatory responses observed with permanent polymer-based drug-eluting stents. In a preliminary study, selected biodegradable or permanent polymer-based sirolimus-eluting stent (SES) formulations were screened for effectiveness in comparison to bare metal stents (BMS) at 28 days. Subsequently, the most favourable SES formulation was compared to commercially available SES (CypherTM) at 28,90 and 180 days to investigate the histopathologic response as well as tissue, blood and organ phar

APA, Harvard, Vancouver, ISO, and other styles

7

Chong, Eric, Kian Keong Poh, Shen Liang, Xu Min Hou, and Huay Cheem Tan. "Eighteen-Month Clinical Safety and Efficacy Outcomes of Sirolimus-, Paclitaxel and Zotarolimus-drug Eluting Stents in Diabetic Patients Undergoing Percutaneous Coronary Intervention for Complex Coronary Artery Stenosis." Annals of the Academy of Medicine, Singapore 39, no. 5 (2010): 381–84. http://dx.doi.org/10.47102/annals-acadmedsg.v39n5p381.

Full text

Abstract:

Introduction: This was a single centre registry study on clinical efficacy and safety of drug-eluting stent (DES) in diabetic patients undergoing percutaneous coronary intervention (PCI) for complex coronary lesions. Materials and Methods: A total of 288 diabetic patients who underwent elective PCI between September 2003 and June 2006 in our centre were enrolled and followed-up for 18 months. Among them, 79 (27.4%) patients received sirolimus-eluting stent (SES), 138 (47.9%) paclitaxel-eluting stent (PES) and 71 (24.7%) zotarolimus-eluting stent (ZES). The endpoints were major adverse cardiac

APA, Harvard, Vancouver, ISO, and other styles

8

Sperling, Christian, Matthias W. Waliszewski, Behrouz Kherad, and Florian Krackhardt. "Comparative preclinical evaluation of a polymer-free sirolimus-eluting stent in porcine coronary arteries." Therapeutic Advances in Cardiovascular Disease 13 (January 2019): 175394471982633. http://dx.doi.org/10.1177/1753944719826335.

Full text

Abstract:

Background: Polymer-free drug-eluting stents (DES) without permanent-polymer coating may be associated with rapid vessel healing, providing a rationale to reduce dual-antiplatelet therapy (DAPT). The aim of the current study was to compare vessel healing of a polymer-free sirolimus-eluting stent (PF-SES), its bare metal stent (BMS) analogue to a permanent polymer-based sirolimus-eluting stent (SES) with proven effectiveness in porcine coronary arteries. Material and methods: An ultrathin-strut cobalt–chromium PF-SES, its BMS analogue and an SES with a permanent polymer were used to study vesse

APA, Harvard, Vancouver, ISO, and other styles

9

Jakobsen, Lars, Evald H. Christiansen, Phillip Freeman, et al. "Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial." Circulation 143, no. 22 (2021): 2155–65. http://dx.doi.org/10.1161/circulationaha.120.052766.

Full text

Abstract:

Background: Target lesion failure remains an issue with contemporary drug-eluting stents. Thus, the dual-therapy sirolimus-eluting and CD34+ antibody–coated Combo stent (DTS) was designed to further improve early healing. This study aimed to investigate whether the DTS is noninferior to the sirolimus-eluting Orsiro stent (SES) in an all-comers patient population. Methods: The SORT OUT X (Combo Stent Versus Orsiro Stent) trial, was a large-scale, randomized, multicenter, single-blind, 2-arm, noninferiority trial with registry-based follow-up. The primary end point target lesion failure was a co

APA, Harvard, Vancouver, ISO, and other styles

10

Otsuka, Fumiyuki, Masataka Nakano, Saami K. Yazdani, Elena Ladich, Frank D. Kolodgie, and Renu Virmani. "Pathology of First-generation Drug-eluting Stents in Humans." Asia Pacific Cardiology 3, no. 1 (2011): 52. http://dx.doi.org/10.15420/apc.2011:3:1:52.

Full text

Abstract:

First-generation sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) have dramatically reduced restenosis, although concern still exists about the long-term safety of this technology since observational studies have shown a steady increase in the rate of late stent thrombosis (LST), an infrequent but catastrophic complication. Although the mechanisms of LST are multifactorial, our laboratory has demonstrated that delayed arterial healing accompanied by poor endothelialisation is the primary pathogical substrate underlying this event. Delayed arterial healing is associated with p

APA, Harvard, Vancouver, ISO, and other styles

11

Otsuka, Fumiyuki, Masataka Nakano, Saami K. Yazdani, Elena Ladich, Frank D. Kolodgie, and Renu Virmani. "Pathology of First-generation Drug-eluting Stents in Humans." Interventional Cardiology Review 6, no. 1 (2011): 28. http://dx.doi.org/10.15420/icr.2011.6.1.28.

Full text

Abstract:

First-generation sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) have dramatically reduced restenosis, although concern still exists about the long-term safety of this technology since observational studies have shown a steady increase in the rate of late stent thrombosis (LST), an infrequent but catastrophic complication. Although the mechanisms of LST are multifactorial, our laboratory has demonstrated that delayed arterial healing accompanied by poor endothelialisation is the primary pathogical substrate underlying this event. Delayed arterial healing is associated with p

APA, Harvard, Vancouver, ISO, and other styles

12

Zhu, Lin, Yi Ning Lv, and Li Yu Wang. "Stent Thrombosis with Biodegradable Polymer Drug-Eluting Stents versus Durable Polymer Sirolimus-Eluting Stents: An Update Meta-Analysis." Cardiology 130, no. 2 (2015): 96–105. http://dx.doi.org/10.1159/000368073.

Full text

Abstract:

Objective: Durable polymer sirolimus-eluting stents (DP-SES) are associated with a low risk of stent thrombosis; biodegradable polymer drug-eluting stents (BP-DES) were designed to reduce these risks. However, their benefits are still variable. Method: We undertook a meta-analysis of randomized trials identified by systematic searches of Medline, Embase, and the Cochrane Database. Results: Eleven studies (9,676 patients) with a mean follow-up of 22.6 months were included. Overall, compared with DP-SES, BP-DES significantly lowered the rate of definite or probable stent thrombosis (RR, 0.73; 95

APA, Harvard, Vancouver, ISO, and other styles

13

Smits, Pieter C. "A Comparison of Drug-eluting Stents for Percutaneous Coronary Intervention – Background, Rationale and Design of the COMPARE Trial." European Cardiology Review 5, no. 2 (2009): 69. http://dx.doi.org/10.15420/ecr.2009.5.2.69.

Full text

Abstract:

Drug-eluting stents (DES) can reduce the risk of restenosis associated with percutaneous intervention procedures. However, the first-generation sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) are associated with a higher rate of stent thrombosis compared with bare-metal stents (BMS). Recently, an everolimus-eluting stent (EES) has been developed and data from randomised, controlled trials have demonstrated the safety and efficacy of the EES in the treatment of coronary artery disease. The randomised, all-comer, real-world COMPARE trial has compared the clinical outcomes achi

APA, Harvard, Vancouver, ISO, and other styles

14

Okumura, Masanori, Yukio Ozaki, Junichi Ishii, et al. "Restenosis and Stent Fracture Following Sirolimus-Eluting Stent (SES) Implantation." Circulation Journal 71, no. 11 (2007): 1669–77. http://dx.doi.org/10.1253/circj.71.1669.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Zhang, Yaojun, Fang Chen, Takashi Muramatsu, et al. "Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease: the Nano randomized trial." Chinese Medical Journal 127, no. 11 (2014): 2153–58. http://dx.doi.org/10.3760/cma.j.issn.0366-6999.20133148.

Full text

Abstract:

Background First generation drug-eluting stents (DES) were associated with a high incidence of late stent thrombosis (ST), mainly due to delayed healing and re-endothelization by the durable polymer coating. This study sought to assess the safety and efficacy of the Nano polymer-free sirolimus-eluting stent (SES) in the treatment of patients with de novo coronary artery lesions. Methods The Nano trial is the first randomized trial designed to compare the safety and efficacy of the Nano polymer-free SES and Partner durable-polymer SES (Lepu Medical Technology, Beijing, China) in the treatment o

APA, Harvard, Vancouver, ISO, and other styles

16

KIMURA, Takeshi. "2. Sirolimus-Eluting Stent (SES) and antiplatelet therapy." Japanese Journal of Thrombosis and Hemostasis 20, no. 3 (2009): 355–59. http://dx.doi.org/10.2491/jjsth.20.355.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Otsuka, Fumiyuki, Masataka Nakano, Elena Ladich, Frank D. Kolodgie, and Renu Virmani. "Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement." Thrombosis 2012 (November 21, 2012): 1–16. http://dx.doi.org/10.1155/2012/608593.

Full text

Abstract:

Several randomized and observational studies have reported steady increase in cumulative incidence of late and very late ST (LST/VLST) following first-generation drug-eluting stents (DES: sirolimus-(SES) and paclitaxel-(PES)) up to 5 years. Pathologic studies have identified uncovered struts as the primary substrate responsible for LST/VLST following DES, where delayed arterial healing is associated with stent struts penetrating into the necrotic core, long/overlapping stents, and bifurcation stenting especially in flow divider region. Grade V stent fracture also induces LST/VLST and restenosi

APA, Harvard, Vancouver, ISO, and other styles

18

Shin, Yonghoon, Yoonsun Won, Taeil Yang, et al. "Safety and Efficacy of Post-Dilation in Percutaneous Coronary Intervention Using Polymer-Free Ultrathin Strut Sirolimus-Probucol Coated Drug-Eluting Stents." Medicina 59, no. 9 (2023): 1649. http://dx.doi.org/10.3390/medicina59091649.

Full text

Abstract:

Background and Objectives: Polymer-free ultrathin strut sirolimus- and probucol-eluting stents (PF-SES) are recognized as safe and effective in diverse patient populations, although the implications of post-dilation during stent implantation remain underexamined. Materials and Methods: In this study, patients implanted with PF-SES at Gachon University Gil Medical Center between December 2014 and February 2018 were evaluated. Major adverse cardiovascular events (MACE), encompassing nonfatal myocardial infarction (MI), nonfatal stroke, and cardiovascular death were identified as primary outcomes

APA, Harvard, Vancouver, ISO, and other styles

19

Chandwani, Prakash, Bhavesh Meel, Rahul Singhal, et al. "Three-Year Outcomes of Biodegradable Polymer-Coated Ultra-Thin (60 µm) Sirolimus-Eluting Stents in Real-World Clinical Practice." Annals of the Academy of Medicine, Singapore 48, no. 5 (2019): 150–55. http://dx.doi.org/10.47102/annals-acadmedsg.v48n5p150.

Full text

Abstract:

Introduction: Although drug-eluting stents (DES) have outclassed the use of bare metal stents, the safety and efficacy of DES at long-term follow-up has still been conflicting because of increased occurrence of late or very late restenosis and stent thrombosis after DES implantation. Hence, the present study was aimed to evaluate the 3-year safety and clinical performance of biodegradable polymer-coated ultra-thin (60 μm) sirolimus-eluting stent (SES) in real-world patients with coronary artery disease (CAD). Materials and Methods: This was a physician-initiated, retrospective, single-centre,

APA, Harvard, Vancouver, ISO, and other styles

20

Pradeepa, P., S. S. Murugan, Sangeetha V. Naveen, and T. S. Kumaravel. "Evaluation of Mechanical Hemolysis of Bare Metallic and Drug-Eluting Cardiovascular Stents." Indian Journal Of Science And Technology 18, no. 13 (2025): 1079–86. https://doi.org/10.17485/ijst/v18i13.645.

Full text

Abstract:

Objectives: To investigate the hemolytic potential of different types of experimental cardiovascular stents [Bare Metal Stents (BMS), Sirolimus Eluting Stents (SES), and Everolimus Eluting Stents (EES)] in an in vitro study using a bovine blood circulatory model. Methods : Fresh bovine blood was circulated through the loop containing the stents, using the peristaltic pump for 6 hours at 37°C at a constant flow of 200 mL/minute. Plasma Free Hemoglobin (PFH) was measured spectrophotometrically at defined intervals. The Normalized Index of Hemolysis (NIH) and the Modified Index of Hemolysis (MIH)

APA, Harvard, Vancouver, ISO, and other styles

21

Kan, Jing, Feng Chen, Li-ya Liu, et al. "Quantitative assessment of late lumen loss after biodegradable polymer and permanent polymer sirolimus-eluting stents implantation." Chinese Medical Journal 126, no. 6 (2013): 1081–85. http://dx.doi.org/10.3760/cma.j.issn.0366-6999.20123385.

Full text

Abstract:

Background Sirolimus-eluting stents (SES) are reported to be associated with reduced late lumen loss (LLL), resulting in less frequent restenosis when compared to bare-metal stent. The current study aimed to assess the difference in LLL between SES with biodegradable and with permanent polymer. Methods From March 2010 to June 2011, 300 consecutive patients having only biodegradable polymers or permanent polymer SES for all diseased vessels were included. Serial quantitative coronary analysis was performed on both the “in-stent” and “segment” area, including the stented segment, as well as both

APA, Harvard, Vancouver, ISO, and other styles

22

Cui, Yuanyuan, Fuhai Zhao, Jiangang Liu, et al. "Zedoary Guaiane-Type Sesquiterpenes-Eluting Stents Accelerate Endothelial Healing Without Neointimal Hyperplasia in a Porcine Coronary Artery Model." Journal of Cardiovascular Pharmacology and Therapeutics 22, no. 5 (2017): 476–84. http://dx.doi.org/10.1177/1074248417696819.

Full text

Abstract:

Objective: The effects of zedoary guaiane-type sesquiterpenes (ZGS)-based eluting stent (ZES) in accelerating reendothelialization and inhibiting neointimal hyperplasia were examined in a porcine coronary artery model. Methods: The ZES was prepared by polymer-free 316L stainless metal stents. Sirolimus-eluting stents (SES) and bare metal stents (BMS) with identical platforms were used as controls. Stents with 15 mm in length and 2.0 to 3.5 mm in diameter were implanted in porcine coronary arteries. Scanning electron microscopy (SEM) and histopathology were performed to assess the reendothelial

APA, Harvard, Vancouver, ISO, and other styles

23

Shetty, Ranjan, Jayesh Prajapati, Umesh Pai, and Kiran Shetty. "Preliminary Evaluation of Clinical and Angiographic Outcomes with Biodegradable Polymer Coated Sirolimus-Eluting Stent inDe NovoCoronary Artery Disease: Results of the MANIPAL-FLEX Study." Scientifica 2016 (2016): 1–8. http://dx.doi.org/10.1155/2016/9324279.

Full text

Abstract:

Objective. The objective of the MANIPAL-FLEX study was to evaluate the feasibility, preliminary safety, and efficacy of the Supraflex sirolimus-eluting stent (SES) implantation, inde novocoronary artery disease, using clinical and quantitative coronary angiography (QCA) follow-ups.Methods. This was a prospective, nonrandomized, multicenter, single-arm study that enrolled 189 patients withde novocoronary artery disease who were treated with the Supraflex SES. Of 189 patients enrolled, the first 61 consecutive patients who consented to a 9-month follow-up evaluation by QCA, irrespective of prese

APA, Harvard, Vancouver, ISO, and other styles

24

Zähringer, Markus, Marc Sapoval, Peter M. T. Pattynama, et al. "Sirolimus-Eluting versus Bare-Metal Low-Profile Stent for Renal Artery Treatment (GREAT Trial): Angiographic Follow-up after 6 Months and Clinical Outcome up to 2 Years." Journal of Endovascular Therapy 14, no. 4 (2007): 460–68. http://dx.doi.org/10.1177/152660280701400405.

Full text

Abstract:

Purpose: To evaluate the patency of sirolimus-eluting stents (SES) compared to bare-metal stents (BMS) in the treatment of atherosclerotic renal artery stenosis (RAS). Methods: Between November 2001 to June 2003, 105 consecutive symptomatic patients (53 men; mean age 65.7 years) with RAS were treated with either a bare-metal (n=52) or a drug-eluting (n=53) low-profile Palmaz-Genesis peripheral stent at 11 centers in a prospective nonrandomized trial. The primary endpoint was the angiographic result at 6 months measured with quantitative vessel analysis by an independent core laboratory. Second

APA, Harvard, Vancouver, ISO, and other styles

25

Monjur, Mohammad Riashad, Christian F. Said, Paul Bamford, Michael Parkinson, Richard Szirt, and Thomas Ford. "Ultrathin-strut biodegradable polymer versus durable polymer drug-eluting stents: a meta-analysis." Open Heart 7, no. 2 (2020): e001394. http://dx.doi.org/10.1136/openhrt-2020-001394.

Full text

Abstract:

ObjectivesDetermine whether an ultrathin biodegradable polymer sirolimus-eluting stent (‘Orsiro’—BP-SES) has clinical benefits over second-generation durable polymer drug-eluting stents (DP-DES).MethodsWe conducted a prospective systematic review and meta-analysis of randomised clinical trials comparing Orsiro BP-SES against DP-DES (PROSPERO Registration: CRD42019147136). The primary outcome was target lesion failure (TLF): composite of cardiac death, target vessel myocardial infarction (TVMI) and clinically indicated target lesion revascularisation (TLR)) evaluated at the longest available fo

APA, Harvard, Vancouver, ISO, and other styles

26

P, Pradeepa, S. Murugan S, V. Naveen Sangeetha, and S. Kumaravel T. "Evaluation of Mechanical Hemolysis of Bare Metallic and Drug-Eluting Cardiovascular Stents." Indian Journal of Science and Technology 18, no. 13 (2025): 1079–86. https://doi.org/10.17485/IJST/v18i13.645.

Full text

Abstract:

Abstract <strong>Objectives:</strong> To investigate the hemolytic potential of different types of experimental cardiovascular stents [Bare Metal Stents (BMS), Sirolimus Eluting Stents (SES), and Everolimus Eluting Stents (EES)] in an in vitro study using a bovine blood circulatory model. <strong>Methods :</strong> Fresh bovine blood was circulated through the loop containing the stents, using the peristaltic pump for 6 hours at 37°C at a constant flow of 200 mL/minute. Plasma Free Hemoglobin (PFH) was measured spectrophotometrically at defined intervals. The Normalized Inde

APA, Harvard, Vancouver, ISO, and other styles

27

Polavarapu, Anurag, Raghava Sarma Polavarapu, Jayesh Prajapati, et al. "Clinical Outcomes from Unselected “Real-World” Patients with Long Coronary Lesion Receiving 40 mm Biodegradable Polymer Coated Sirolimus-Eluting Stent." Scientifica 2015 (2015): 1–6. http://dx.doi.org/10.1155/2015/613089.

Full text

Abstract:

Background. Long lesions being implanted with drug-eluting stents (DES) are associated with relatively high restenosis rates and higher incidences of adverse events.Objectives. We aimed to examine the safety and efficacy of the long (40 mm) biodegradable polymer coated Indolimus sirolimus-eluting stent (SES) in real-world patients with long coronary lesions.Methods. This study was observational, nonrandomized, retrospective, and carried out in real-world patients. A total of 258 patients were enrolled for the treatment of long coronary lesions, with 40 mm Indolimus. The primary endpoints in th

APA, Harvard, Vancouver, ISO, and other styles

28

Madaan, Amit, S. K. Sinha, M. M. Razi, et al. "Study to assess clinical outcomes of an everolimus-eluting stent (EES) versus a sirolimus-eluting stent (SES)." Indian Heart Journal 67 (December 2015): S53. http://dx.doi.org/10.1016/j.ihj.2015.10.128.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Ahmad, Mansoor, Agrawal Durgesh, Krunalkumar Patel, et al. "D-16 | Biodegradable Polymer Sirolimus Eluting Stent (DP-SES) versus Durable Polymer Everolimus Eluting Stent (DP-EES)." Journal of the Society for Cardiovascular Angiography & Interventions 2, no. 3 (2023): 100871. http://dx.doi.org/10.1016/j.jscai.2023.100871.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Kang, Jeon Min, Song Hee Kim, Yeon Joo Choi, et al. "Sirolimus-eluting cobalt–chrome alloy stent suppresses stent-induced tissue hyperplasia in a porcine Eustachian tube model." Scientific Reports 12, no. 1 (2022). http://dx.doi.org/10.1038/s41598-022-07471-2.

Full text

Abstract:

AbstractVarious preclinical studies with developed Eustachian tube (ET) stents are in progress but have not yet been clinically applied. ET stent is limited by stent-induced tissue hyperplasia in preclinical studies. The effectiveness of sirolimus-eluting cobalt–chrome alloy stent (SES) in suppressing stent-induced tissue hyperplasia after stent placement in the porcine ET model was investigated. Six pigs were divided into two groups (i.e., the control and the SES groups) with three pigs for each group. The control group received an uncoated cobalt–chrome alloy stent (n = 6), and the SES group

APA, Harvard, Vancouver, ISO, and other styles

31

Ouyang, Hang, Xuehui Zeng, Chunlei Zhang, et al. "A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients." Journal of Cardiothoracic Surgery 16, no. 1 (2021). http://dx.doi.org/10.1186/s13019-021-01452-8.

Full text

Abstract:

Abstract Objective We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. Methods A systematic search of publications about randomized controlled trials (RCTs) focused on diabetic patients received EES, SES or PES was conducted. We evaluated the following indicators: target vessel revascularization (TVR), target lesion revascularization (TLR), late luminal loss (LLL), stent thrombosis (ST), myocardial infarction (MI), all-cause mortal

APA, Harvard, Vancouver, ISO, and other styles

32

Otsuji, Hideaki, Kazushige Kadota, Tsuyoshi Goto, et al. "Abstract 18297: Peri-stent Contrast Staining After Drug-eluting Balloon Angioplasty for Treatment of Coronary In-stent Restenosis." Circulation 126, suppl_21 (2012). http://dx.doi.org/10.1161/circ.126.suppl_21.a18297.

Full text

Abstract:

Background: Peri-stent contrast staining (PSS) induced by sirolimus-eluting stent (SES) implantation has been reported and the PSS rate was about 2%. It is said that PSS is an abnormal vessel reaction and is related to stent thrombosis. However, it remains unknown whether PSS arises after drug-eluting balloon (DEB) angioplasty. We report on PSS which arose after DEB angioplasty in the in-stent restenosis (ISR) lesion in relation to previously deployed stents. Methods: From September 2008 to October 2011, 378 consecutive patients with 453 lesions (42 de novo and 411 ISR) underwent DEB angioplas

APA, Harvard, Vancouver, ISO, and other styles

33

Shah, A., and N. S. Kumar. "O061 A dilemma faced by vascular surgeons - biodegradable versus non-biodegradable drug-releasing stents: a systematic review and meta-analysis." British Journal of Surgery 110, Supplement_3 (2023). http://dx.doi.org/10.1093/bjs/znad101.061.

Full text

Abstract:

Abstract Introduction Vascular stents are the best-known interventional treatment for cardiovascular disease, with variation in available stents increasing significantly over time. Despite the rapidity of new prototype releases, critical cross-comparisons fail to uphold the same rate, therefore causing confusion for vascular surgeons. Research is lacking between biodegradable-polymer sirolimus-eluting stents (BP-SES) and permanent-polymer sirolimus-eluting stents (PP-SES). Subsequently, a systematic review with meta-analysis was conducted evaluating clinical outcomes. Methods Medline, Embase,

APA, Harvard, Vancouver, ISO, and other styles

34

Ichikawa, Minoru, Shohei Yoshima, Yoshizumi Takei, et al. "Abstract 458: Poor Progression of in-Stent Neoatherosclerosis in Patients With Everolimus-Eluting Stent Implantation: Coronary Angioscopic Observation." Arteriosclerosis, Thrombosis, and Vascular Biology 34, suppl_1 (2014). http://dx.doi.org/10.1161/atvb.34.suppl_1.458.

Full text

Abstract:

Very late stent thrombosis (VLST) is one of the most serious issues in the era of drug-eluting stents (DES). VLST has been attributed to delayed neointimal stent coverage (NSC) due to bio-suppressive drugs and vulnerability of in-stent neoatherosclerosis. The latter was recently proposed by pathologists as in-stent atherosclerotic lesions at chronic phase of coronary stenting. The aim of this study was angioscopic observation of in-stent vessel wall at 3 years after implantation of various generations of DES. Enrolled were 37 stented segments in 26 patients with stable angina (25 Cypher siroli

APA, Harvard, Vancouver, ISO, and other styles

35

Lee, SY, MH Kim, CM Ahn, et al. "Abstract 2156: In-Stent Restenosis after Sirolimus-Eluting Stent Implantation is Related to Coronary Stent Fracture." Circulation 116, suppl_16 (2007). http://dx.doi.org/10.1161/circ.116.suppl_16.ii_467-c.

Full text

Abstract:

Background and objectives : It has been reported in few studies about relationship between sirolimus-eluting stent (SES) fracture and in-stent restenosis (ISR). Therefore, authors investigated clinical characteristics of the SES fracture and the association with ISR. Subjects and Methods : From December 2003 to February 2006, implantation and follow-up coronary angiography(CAG) for 796 sirolimus-eluting stents were carried out in Severance hospital. We reviewed clinical, procedural and structural factors which might affect SES fracture and ISR. Results : Twenty four fractures after 796 SES imp

APA, Harvard, Vancouver, ISO, and other styles

36

Kereiakes, Dean J., Robert L. Feldman, A. J. J. Ijsselmuiden, et al. "Safety and Effectiveness of the SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions: Results of the OPTIMIZE Randomized Study." Circulation: Cardiovascular Interventions, August 6, 2021. http://dx.doi.org/10.1161/circinterventions.121.010609.

Full text

Abstract:

Background: The SVELTE fixed-wire and rapid exchange bioresorbable-polymer sirolimus-eluting coronary stent systems (SVELTE sirolimus-eluting stent [SES]) are novel, low-profile devices designed to facilitate direct stenting, transradial access, and enhance procedural efficiencies. Methods: Eligible subjects (N=1639) scheduled to undergo percutaneous coronary intervention for non–ST-segment–elevation myocardial infarction or stable coronary artery disease were randomly assigned (1:1) to treatment with either SVELTE SES or a control durable polymer everolimus-eluting coronary stent. The primary

APA, Harvard, Vancouver, ISO, and other styles

37

Shah, A., and N. Kumar. "1247 A Vascular Surgeon's Dilemma - Biodegradable Versus Non-Biodegradable Drug Releasing Stents: A Systematic Review and Meta Analysis." British Journal of Surgery 110, Supplement_7 (2023). http://dx.doi.org/10.1093/bjs/znad258.009.

Full text

Abstract:

Abstract Aim Vascular stents are the best-known interventional treatment for cardiovascular disease, and variation in available stents has increased significantly over time. Despite the rapidity of new prototype releases, critical cross-comparisons fail to maintain the same rate, therefore causing confusion for vascular surgeons. Research is most notably lacking between biodegradable-polymer sirolimus-eluting stents (BP-SES) and permanent-polymer sirolimus-eluting stents (PP-SES). Consequently, a systematic review with meta-analysis was conducted evaluating clinical outcomes. Method Medline, E

APA, Harvard, Vancouver, ISO, and other styles

38

Nakamura, Sunao, Mizuki Hirose, Jang-Ho Bae, et al. "Abstract 2164: Impact of Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent on the Outcome of Patients with Sirolimus-Eluting Stent Failure: Multicenter Registry in Asia." Circulation 116, suppl_16 (2007). http://dx.doi.org/10.1161/circ.116.suppl_16.ii_469-c.

Full text

Abstract:

Purpose: To evaluate the Sirolimus-eluting stent (SES) and Paclitaxel-eluting stent (PES) on the outcome of patients with SES failure (SES-F). Methods: A total of 520 patients with 609 SES-F lesions (male 74.8%, mean age 72.1 yrs, LMT 7.1%, LAD 47.6%, LCX 25.0%, RCA 16.2%, SVG 4.1%) were treated with SES (mean lesion length 26.1±12.6 mm, mean stent length 31.3±15.9mm) and PES (mean lesion length 28.3±12.2 mm, mean stent length 32.9±19.3 mm). We evaluate immediate and long-term clinical results by 6 and 12 months angiography. Results: The baseline clinical characteristics between 2 groups were

APA, Harvard, Vancouver, ISO, and other styles

39

Dvir, Danny, Hironori Kitabata, Israel M. Barbash, et al. "Abstract 18645: Axial Integrity of Coronary Stents: Evaluation Using Intravascular Ultrasound." Circulation 126, suppl_21 (2012). http://dx.doi.org/10.1161/circ.126.suppl_21.a18645.

Full text

Abstract:

Background: Longitudinal stent deformation (i.e. the axial shortening or lengthening of a stent after implantation) is increasingly reported. However, the axial integrity of stents has not been systematically studied using intravascular ultrasound (IVUS). Methods: Consecutive coronary artery disease patients who underwent IVUS analysis after drug-eluting stent implantation for de-novo lesions were evaluated. Stent length was studied using automatic pullback of an IVUS catheter (Boston Scientific Corp/SCIMED) and was further analyzed for change in length (IVUS - label) (mm), the absolute change

APA, Harvard, Vancouver, ISO, and other styles

40

Sakurai, Ryota, Brian K. Courtney, Masao Yamasaki, et al. "Abstract 2770: Neointimal Hyperplasia Patterns Among 3 Drug-Eluting Stents: A Comparative Intravascular Ultrasound Analysis of Everolimus-, Sirolimus-, and Paclitaxel-Eluting Stents." Circulation 116, suppl_16 (2007). http://dx.doi.org/10.1161/circ.116.suppl_16.ii_615-a.

Full text

Abstract:

Background The amount of neointimal hyperplasia as well as the percentage of neointimal stent surface coverage may be different among various types of drug-eluting stents (DES). Methods From the Stanford University Intravascular Ultrasound (IVUS) Core Laboratory database, this study consisted of the patients enrolled in prospective, multicenter clinical trials with DES deployment for de novo coronary lesions and 3-D IVUS at 8- to 9-month follow-up as part of their study protocol. In these cases, 155 single DES: (1) an 18-mm everolimus-eluting (EES, 52 stents in 50 patients); (2) an 18-mm sirol

APA, Harvard, Vancouver, ISO, and other styles

41

Umeda, Hisashi, Tomoko Gochi, Mitsuhiro Iwase, Hideo Izawa, Mitsuhiro Yokota, and Toyoaki Murohara. "Abstract 5954: Does Sirolimus-Eluting Stent Implantation Lead to an Increased Risk of Stent Fracture?" Circulation 118, suppl_18 (2008). http://dx.doi.org/10.1161/circ.118.suppl_18.s_1037-b.

Full text

Abstract:

Stent fracture (SF) of sirolimus-eluting stents (SES) has emerged recently in literature and shown to be associated with an increased risk of restenosis. We sought to assess whether the use of SES increases the frequency of SF compared with bare-metal stents (BMS). A consecutive series of 499 lesions of 434 patients undergoing SES implantation (total stent length: 10 to 40 mm) followed by coronary angiography at 6 to 9 months were compared with 137 consecutive patients (147 lesions) treated with BMS (total stent length: 10 to 40 mm) which consists of stent platform of SES. SF was defined as si

APA, Harvard, Vancouver, ISO, and other styles

42

Shutta, R., M. Nishino, A. Kawamura, et al. "Negative impact of ultra-thin strut on neointimal coverage condition within one year after implantation as compared to thin sturt in biogradable-polymer sirorimus eluting stents." European Heart Journal 41, Supplement_2 (2020). http://dx.doi.org/10.1093/ehjci/ehaa946.0319.

Full text

Abstract:

Abstract Background BIOSCIENCE randomized trial which compared biodegradable-polymer sirolimus-eluting stents with ultra-thin (60μm) strut (ultra-thin BP-SES) and durable-polymer everolimus-eluting stents with thin (81μm) strut (thin DP-EES) have reported that definite stent thrombosis within 1 year had more frequently occurred in ultra-thin BP-SES (0.9%) than in thin DP-EES group (0.4%) although it was not statistically significant. It suggests that neointimal coverage after stent implantation within 1 year might be different between ultra-thin BP-SES and thin DP-EES. Recently, two types of b

APA, Harvard, Vancouver, ISO, and other styles

43

Yamaguchi, Koji, Tetsuzo Wakatsuki, Akira Takashima, et al. "Abstract 13607: Differential Response of Local Coagulation after Implantation of New Generation Drug-Eluting Stents Compared with Sirolimus-Eluting Stent." Circulation 130, suppl_2 (2014). http://dx.doi.org/10.1161/circ.130.suppl_2.13607.

Full text

Abstract:

Purpose: We have previously demonstrated local persistent hypercoagulation after sirolimus-eluting stent (SES) implantation by measuring plasma prothrombin fragment F1+2(frF1+2) levels. The aim of this study is to examine local coagulation response after biolimus-eluting stent (BES) and everolimus-eluting stent (EES) implantation. Methods: Sixty-eight patients who were treated with stents about eight months earlier to the mid-segment of the left anterior descending coronary artery, with no evidence of restenosis, were studied (BES: 12pts, EES: 15pts, SES: 23pts, and BMS: 18pts). We measured pl

APA, Harvard, Vancouver, ISO, and other styles

44

Dan, Kazuhiro, Hector M. Garcia-Garcia, Paul Kolm, et al. "Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions." Circulation: Cardiovascular Interventions 13, no. 9 (2020). http://dx.doi.org/10.1161/circinterventions.120.009189.

Full text

Abstract:

Background: The ultrathin-strut bioresorbable-polymer sirolimus-eluting stent (BP-SES) demonstrated comparable performance to durable-polymer everolimus-eluting stent (DP-EES) in randomized controlled trials. The purpose of this study was to evaluate the performance of a BP-SES compared with a DP-EES in calcified or small vessel lesions, which represent higher risk of restenosis. Methods: From the pooled BIOFLOW (BIOFLOW-II, IV, and V; BIOTRONIK - A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treat

APA, Harvard, Vancouver, ISO, and other styles

45

Nakamura, Sunao, Shotaro Nakamura, Hisao Ogawa, et al. "Abstract 2520: Drug-Eluting Stents for the Treatment of Chronic Total Occlusion: A Comparison with Sirolimus, Paclitaxel, Zotarolimus, EPC Capture and Everolimus-Eluting Stent: Multicenter Registry in Asia." Circulation 118, suppl_18 (2008). http://dx.doi.org/10.1161/circ.118.suppl_18.s_737.

Full text

Abstract:

The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES), EPC capture (ECS) and Everolimus-eluting stent (EES) on the outcome of patients with chronic total occlusion (CTO). A prospective analysis of 1149 patients with 1183 CTOs (396 SES, 526 PES, 177 ZES, 41 ECS, 43 EES) in five high volume Asian centers after successful recanalization of CTO was performed. The study endpoints were 30 days and 9 months major adverse cardiac events (MACE), 9 months angiographic restenosis and target lesion revascularization (TLR). See table for clinica

APA, Harvard, Vancouver, ISO, and other styles

46

Ploumen, Eline H., Tineke H. Pinxterhuis, Rosaly A. Buiten, et al. "Final 5‐Year Report of the Randomized BIO‐RESORT Trial Comparing 3 Contemporary Drug‐Eluting Stents in All‐Comers." Journal of the American Heart Association, November 8, 2022. http://dx.doi.org/10.1161/jaha.122.026041.

Full text

Abstract:

Background In a previous trial, higher 5‐year mortality was observed following treatment with biodegradable polymer Orsiro sirolimus‐eluting stents (SES). We assessed 5‐year safety and efficacy of all‐comers as well as patients with diabetes treated with SES or Synergy everolimus‐eluting stents (EES) versus durable polymer Resolute Integrity zotarolimus‐eluting stents (ZES). Methods and Results The randomized BIO‐RESORT (Comparison of Biodegradable Polymer and Durable Polymer Drug‐Eluting Stents in an All Comers Population) trial enrolled 3514 all‐comer patients at 4 Dutch cardiac centers. Pat

APA, Harvard, Vancouver, ISO, and other styles

47

Chang, Chun‐Chin, Wei‐Ting Sung, Ya‐Wen Lu, et al. "Real‐World Clinical Performance of a Novolimus‐Eluting Stent Versus a Sirolimus‐Eluting Stent." Clinical Cardiology 47, no. 7 (2024). http://dx.doi.org/10.1002/clc.24317.

Full text

Abstract:

ABSTRACTIntroductionThe DESyne novolimus‐eluting coronary stent (NES) is a new‐generation drug‐eluting stent (DES) that is widely used, but clinical data are rarely reported for this stent. We compared the safety and effectiveness of the DESyne NES and the Orsiro bioresorbable polymer sirolimus‐eluting stent (SES) in patients undergoing percutaneous coronary intervention (PCI).MethodsThis was a retrospective, single‐center, observational study. Between July 2017 and December 2022, patients who presented with chronic or acute coronary syndrome undergoing PCI with DESyne NES or Orsiro SES were c

APA, Harvard, Vancouver, ISO, and other styles

48

Otake, Hiromasa, Fumiaki Ikeno, Toshiro Shinke, et al. "Abstract 4756: Evaluation of the Peri-strut Low Intensity Area Following Sirolimus- and Paclitaxel-Eluting Stents Implantation: Insights From an Optical Coherence Tomography Study in Humans." Circulation 120, suppl_18 (2009). http://dx.doi.org/10.1161/circ.120.suppl_18.s1000-b.

Full text

Abstract:

Background: In previous pathological studies, paclitaxel-eluting stents (PES) showed greater fibrin deposition around stent struts, while sirolimus-eluting stent (SES) showed predominance of inflammatory cells with less fibrin deposition than PES. However, there are limited in-vivo data clarifying those qualitative differences in the process of vascular healing after 1st-generation drug-eluting stents (DES) implantation. A recent animal study has shown that peri-strut low intensity area (PLIA) seen in optical coherence tomography (OCT) imaging might represent the process of hyaluronic acid and

APA, Harvard, Vancouver, ISO, and other styles

49

Ibrahim, Karim Mohamed Fahmy Mohamed, Raghda Ghonimy El Sheikh, Mai Abdulmonaem Salama, Medhat Mohamed Ashmawy, and Hatem Mohamed El-Sokkary. "Percutaneous Coronary Intervention with Everolimus-Eluting Versus Sirolimus-Eluting Stents in Diabetic Patients Presented with Acute Coronary Syndromes: A Short-term Comparative Clinical Outcome Study." Journal of Advances in Medicine and Medical Research, September 5, 2022, 486–95. http://dx.doi.org/10.9734/jammr/2022/v34i2131567.

Full text

Abstract:

Background: The use of drug-eluting stents (DES) resulted in innovative progress in the field of interventional Cardiology. Nowadays, the most common indication for coronary stenting is acute coronary syndromes (ACS) due to the better clinical consequences of PCI compared with conservative management. However, in diabetic patients, there is a large debate in the literature regarding the selection of an optimal drug-eluting stent. Aim: This work aimed to compare short term clinical outcome post-percutaneous Coronary intervention with Everolimus-eluting stents (EES) versus Sirolimus-elutin

APA, Harvard, Vancouver, ISO, and other styles

50

Wang, Geng, Yi Li, Wen Lu, et al. "Vascular Healing After Biodegradable Polymer Sirolimus‐Eluting Versus Durable Polymer Everolimus‐Eluting Stents in Chronic Total Occlusions." Catheterization and Cardiovascular Interventions, January 29, 2025. https://doi.org/10.1002/ccd.31423.

Full text

Abstract:

ABSTRACTBackgroundBiodegradable polymer stents may reduce the risk of neoatherosclerosis and stent thrombosis. Limited data is available for biodegradable polymer sirolimus‐eluting stent (BP‐SES) and durable polymer drug‐eluting stents (DP‐EES) in chronic total occlusions (CTO).AimThis study was to evaluate healing patterns of BP‐SES versus DP‐EES in CTO at 3 and 13 months based on optical coherence tomography (OCT).MethodsThe TARGET‐CTO study is a prospective, multicenter, randomized noninferiority controlled trial for BP‐SES compared to DP‐EES in CTO. In the current predefined subanalysis, 4

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!